The vascular endothelium compensates for oxidant stress by increasing the activity of antioxidant enzymes such as glucose-6-phophate dehydrogenase (G6PD). G6PD provides reducing equivalents of NAPDH to maintain glutathione stores and modulates nitric oxide synthase (eNOS) activity. To determine whether deficient G6PD activity perturbs these responses, we treated bovine aortic endothelial cells with dehydroepiandrosterone or an antisense oligodeoxynucleotide to G6PD mRNA to decrease G6PD activity and expression. When exposed to hydrogen peroxide, reactive oxygen species (ROS) accumulation was increased in G6PD-deficient cells compared with those with normal activity. To determine the source of increased oxidant stress in G6PD-deficient cells, we used inhibitors of ROS generation, which suggested that eNOS was contributing to ROS production. Treatment with L-NMMA, an inhibitor of eNOS mediated-nitric oxide (NO) but not superoxide, production confirmed this observation; in contrast to L-NAME, L-NMMA promoted ROS generation in G6PD-deficient cells. In addition, deficient G6PD activity was associated with a decrease in endothelium-derived bioavailable NO in response to the agonists A23187 and bradykinin as demonstrated by decreased endothelial cGMP and nitrate/nitrite levels. Enhanced ROS accumulation and decreased NO bioavailability may represent one mechanism by which G6PD deficiency contributes to vascular oxidant stress and endothelial dysfunction.
G6PD has long been recognized as an antioxidant enzyme in erythrocytes, which have no other source of NADPH, and has recently been demonstrated to be important in the defense against oxidant stress in nucleated cells. G6PD expression is induced in cells treated with agents, or mechanical forces, which increase ROS production or deplete GSH levels (1, 2) . Furthermore, overexpression of G6PD has been shown to enhance resistance to both oxidative-and nitrosative-stress-mediated apoptosis (3, 4) . G6PD deficiency, the most common enzymopathy worldwide, is associated with increased cellular oxidant stress. Complete G6PD deficiency has been surmised to be lethal but has been created experimentally by targeted disruption of the G6PD gene in mouse embryonic stem cells. These G6PD null cells are viable in culture but remain exquisitely sensitive to oxidant stressors (5) . Similarly, fibroblasts obtained from G6PD-deficient patients demonstrate premature senescence in culture that has been attributed to increased levels of ROS (6) . In fact, it has been shown in fibroblasts that a 40%-70% inhibition of G6PD activity results in a 30%-40% decrease in NADPH levels (7) , and this, in turn, is a sufficient loss of cellular-reducing equivalents to sensitize cells to hydrogen peroxide (H 2 O 2 )-mediated cell death (8) .
As deficient G6PD activity depletes cellular stores of NADPH, enzymes that require NADPH as a cofactor for optimal activity, such as nitric oxide synthase(s), may appear dysfunctional. Vascular endothelial cells constitutively express nitric oxide synthase (eNOS) that forms NO in the presence of oxygen via a five-electron oxidation of the terminal guanidino nitrogen of Larginine. eNOS binds NADPH, flavin adenine dinucleotide, flavin mononucleotide, L-arginine, a heme moiety, and tetrahydrobiopterin (BH 4 ) (9) . BH 4 synthesis itself is also dependent on available NADPH. Diminished NADPH stores may, therefore, influence eNOS activity directly, as well as indirectly, by decreasing BH 4 salvage via the NADPH-dependent dihydrofolate reductase pathway (10) 
NOS isoforms have been shown to produce superoxide and hydrogen peroxide when the intracellular milieu contains inadequate L-arginine or BH 4 . For example, at low concentrations of L-arginine, nNOS-transfected human kidney 293 cells generated superoxide concomitant with diminished NO production (11) . Similarly, in a cell-free system, eNOS, in the absence of BH 4 , has been shown to produce superoxide in preference to NO (12, 13) . This observation was confirmed in U937 cells with impaired BH 4 synthesis that were transfected with eNOS (9) . In the present work, we demonstrate that endothelial cells with deficient G6PD activity-and, hence, reduced NADPH levels-experience increased oxidant stress resulting from endogenous eNOSmediated ROS production, which is accompanied by a decrease in endothelial-derived bioavailable NO.
MATERIALS AND METHODS

Cell culture and transfections
Bovine aortic endothelial cells (BAEC) (Cell Systems Co, Kirkland, WA) were grown to confluence in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. Cells were passaged twice weekly by harvesting with 0.5% trypsin:EDTA. Experiments were conducted on cells between passages 4-12. In some experiments, cells were pretreated with dehydroepiandrosterone (DHEA) (100 µM) for 24 h to decrease G6PD activity or transfected with an antisense phosphorothioate oligodeoxynucleotide to G6PD mRNA (5'-AGGUCACCCGAUGCACCCAUGAUGA-3') (Sequitor, Inc., Natick, MA) to decrease G6PD expression. Cells were transfected for 5 h by using Oligofectin I (13.2 µl/ml media) as the vehicle in serum-free, antibiotic-free Opti-MEM  media (Gibco-BRL, Rockville, MD), or by using Oligofectin I alone. Cells were then washed twice in serum-free media and transferred to full-growth media for 48 h before being assayed.
DCF fluorescence
Cells were grown to confluence in 96-well plates, washed once with phosphate buffered saline (0.9%), and then incubated with 20 µM 6-carboxy-2'-7' dichlorodihydrofluorescein diacetate di(acetoxymethyl) ester (Molecular Probes, Eugene, OR) for 1 h at 37Û&%$(&ZHUHH[SRVHGWR H 2 O 2 (100 µM), and cellular ROS accumulation over 4 h was determined in a microplate fluorimeter (SpectraMax Gemini, Molecular Devices, Sunnyvale, CA) (14) . To examine the contribution of the flavin-containing enzymes, eNOS, cyclooxygenase, and xanthine oxidase, to ROS production, we treated cells with diphenylene iodonium (10 µM), L-NAME (1 mM) or L-NMMA (100 µM), indomethacin (10 µM), and oxypurinol (100 µM), respectively, in selected experiments, and we determined ROS generation.
Intacellular glutathione determination
We measured intracellular glutathione (GSH) and total glutathione (GSH + GSSG) levels by using the Bioxytech GSH-400 enzymatic method (OXIS) according to the manufacturer's instructions. Total cellular protein was precipitated in 5% metaphosphoric acid and centrifuged, and the supernatant was isolated for measurements. Sample protein content was determined before precipitation by metaphosphoric acid, and activity results were standardized to protein levels (15) .
Cellular glutathione peroxidase and glutathione reductase activities
Cellular glutathione peroxidase and glutathione reductase activities were determined by using the Bioxytech GPx-340 assay (OXIS) and GR-340 assay (OXIS), respectively. Briefly, to determine glutathione peroxidase activity, we scraped cells from the plate and homogenized them in cold assay buffer (50 mM Tris-HCl, pH 7.5; 5 mM EDTA; 1 mM dithiothreitol). Homogenates were centrifuged, and the supernatant was stored on ice. Glutathione peroxidase activity was determined indirectly by measuring the oxidation of NADPH to NADP + at 340 nm (Beckman DU 640B spectrophotometer, Beckman Coulter, Inc., Fullerton, CA) that occurs over time with recycling oxidized glutathione. To determine glutathione reductase activity, cells were scraped from the plate and homogenized in cold assay buffer (50 mM potassium phosphate, pH 7.5; 1 mM EDTA). The supernatant was isolated and stored on ice. Glutathione reductase activity was measured by the oxidation of NADPH to NADP + at 340 nm over time. Activity results were standardized to cellular protein levels to facilitate comparisons between groups (15).
G6PD activity
G6PD activity was measured as previously described (16) . Cells were washed twice with phosphate buffered saline (0.9%), scraped from the plate in 5 ml assay buffer (50 mM Tris, 1 mM MgCl, pH 8.1), and centrifuged at 2000 x g at 4Û& IRU PLQ (Q]\PH DFWLYLW\ ZDV determined by using a plate-reader spectrophotometer (ThermoMax Microplate Reader, Molecular Devices, Menlo Park, CA) by measuring the rate of increase of absorbance at 340 nm from the conversion of NADP + to NADPH by either G6PD or 6-phosphogluconate dehydrogenase (6-PGD). Substrate concentrations used were glucose-6-phosphate (200 µM), 6-phosphogluconate (200 µM), and NADP + (100 µM). Protein levels were determined for each sample (15) , and activity results were standardized to protein concentration.
NADPH determination
NADPH levels were determined spectrophotometrically based on the measurement of the absorbance of the reduced coenzyme at 340 nm (Beckman DU 640B spectrophotometer, Beckman Coulter, Inc., Fullerton, CA) (17) . Cells were washed three times with phosphate buffered saline (0.9%) and scraped from the plate. The cells were then resuspended with 0.15 ml buffer containing 0.1M Tris-HCl, pH 8.0; 0.01M EDTA; and 0.05% (v/v) Triton X-100. The suspension was sonicated on ice for 2 min and centrifuged at 5,000 rpm at 4Û&IRUPLQ$Q initial reading of the sample at 340 nm measured total NADPH and NADH levels in the sample. To assay for NADH alone, we incubated an aliquot of the extract (50 µl) with glutathione reductase (5.0 IU) in 0.1 M phosphate buffer, pH 7.6, containing 0.05 M EDTA and (0.5% v/v) Triton X-100 at 25Û&IRUPLQ7RVWDUWWKHUHDFWLRQ0JOXWDWKLRQH*66*ZDVDGGHG and incubated for an additional 5 min. NADPH levels were calculated as the difference between total pyridine nucleotides in the sample and NADH levels.
G6PD and eNOS immunoblotting
Cells were harvested and centrifuged at 1000 x g at 4Û&IRUPLQDIWHUZKLFKWKHVXSHUQDWDQW was discarded and the samples were frozen at -80 °C overnight. The pellet was homogenized and 25 µg cell protein per sample was added per lane. Protein was size-fractionated electrophoretically with SDS-polyacrylamide gel electrophoresis on a 10% gel and transferred to nitrocellulose membranes blocked with 5% skim milk solution. The membranes were incubated with 1:1,000 dilution of a polyclonal rabbit anti-G6PD antibody (Sigma) or with a 1:1,000 dilution of a monoclonal mouse anti-eNOS antibody (BD Transduction Laboratories, Franklin Lakes, NJ) and were visualized with the ECL detection system (Amersham).
eNOS activity
We measured NOS activity by the conversion of L-[
3 H]-arginine to -L-[ 3 H]-citrulline in the presence of saturating co-factors as described previously (18) . BAEC were scraped from the plate, centrifuged at 1000 x g at 4Û& IRU PLQ DQG IUR]HQ RYHUQLJKW DW -80Û& &HOOV ZHUH thawed and homogenized in the presence of dithiothreitol and protease inhibitors in buffer containing 0.32 mM sucrose, 0.5 mM EDTA, and 20 mM HEPES, pH 7.0. The homogenate was centrifuged at 1000 x g at 4Û& IRU PLQ DQG WKH VROXEOH IUDFWLRQ ZDV DGGHG WR D VROXWLRQ containing 20 mM NADPH, 0.05 mM L-arginine, 0.03 mM BH 4 , 1 mM CaCl 2 , 30 U/ml calmodulin, and 2.25 µCi/ml 2,3,4,5'-[
3 H]arginine. The reaction mixture was incubated for 60 min at 37Û&and we stopped the reactions by using 1.5 ml ice-cold buffer (2 mM EDTA, 5 mM HEPES, pH 5.5). We passed samples over a Na + -exchange column (Dowex, Mallinkrodt Baker Inc., Phillipsburg, NJ, AG50WX-8) and determined radioactivity of the eluate by using a liquid scintillation counter. eNOS activity is expressed as pmol of L-citrulline per mg cell protein per minute.
CGMP, nitrate, and nitrite measurements
We pretreated confluent BAEC with 0.5 mM isobutylmethylxanthine (IBMX) at 37Û& IRU min. They were then stimulated with A23187 (5 µM), bradykinin (5 µM), or diethylamine NONOate (1 µM) for 10 min in the presence of IBMX. The reaction was stopped by the addition of ice-cold 6% trichloroacetic acid. After three freeze-thaw cycles, the cells were scraped from the plate. The supernatant fractions of the cell lysates were extracted with water-saturated ether, dried with nitrogen gas at room temperature, and acetylated. Cyclic GMP levels were quantitated by using a cGMP enzyme immunoassay kit (Cayman Chemical Co., Ann Arbor, MI). Nitrate and nitrite were assayed by using a fluorometric assay kit (Cayman Chemical Co.).
Statistical analysis
Data are expressed as mean ± SE. Comparison between groups was performed by Student's paired two-tailed t-test. A P value of <0.05 was considered significant.
RESULTS
Oxidant stress and endothelial cells
To characterize the response of BAEC to oxidant stress, cells were exposed to H 2 O 2 (100 µmol/L) and ROS accumulation, as determined by DCF fluorescence, was measured every 60 min for 4 h. H 2 O 2 significantly increased DCF fluorescence in a time-dependent manner with a maximum increase in fluorescence observed following 4 h of stimulation (186.2 ± 10.3 vs. 617.9 ± 62.9 arbitrary fluorescence units (AFU), n=8, P<0.01) (Fig. 1A) . At 4 h, this response was associated with a decrease in intracellular GSH levels (360.5 ± 13.1 vs. 227.4 ± 3.5 µmol/L/mg protein, n=4, P<0.0001) (Fig. 1B) and a concomitant increase in G6PD activity (116.6± 6.5 vs. 248.2 ± 24.0 units/6 min/mg protein, n=6, P<0.0004) (Fig. 1C) . Total glutathione levels (GSH + GSSG) (Table 1) were not significantly different between untreated and H 2 O 2 -treated cells (422.9 ± 7.2 vs. 403.1 ± 14.2 µmol/L/mg protein, n=4, P=NS), and this finding suggests that there was an increase in cellular GSSG levels. This conclusion was supported by an observed increase in cellular glutathione peroxidase activity (316.7 ± 46.8 vs. 1474.0 ± 140.1 mU/mg protein, n=3, P<0.002). Glutathione reductase activity was similarly increased in cells exposed to H 2 O 2 (88.4 ± 11.0 vs. 145.6 ± 0.8 mU/mg protein, n=3, P<0.007), which thereby confirms enhanced glutathione recycling in the setting of increased oxidant stress. As longer exposure to H 2 O 2 resulted in cell death (data not shown), a 4-h timepoint was chosen for subsequent experiments.
Inhibition of G6PD activity and endothelial cell oxidant stress
To determine whether deficient G6PD activity adversely influenced the endothelial response to oxidant stress, we treated BAEC with dehydroepiandrosterone (DHEA) (100 µM), a noncompetitive inhibitor of the enzyme (19) . Treatment with DHEA for 24 h significantly decreased G6PD activity (116.6 ± 6.0 vs. 30.1 ± 6.0 units/6 min/mg protein, n=6, P<0.0001) ( Fig. 2A) (Fig. 3A) . In DHEA-treated cells, the H 2 O 2 -mediated increase in ROS accumulation at 4 h was partially inhibited by pretreatment with the antioxidant Nacetylcysteine (30 mmol/L) (1090.3 ± 121.1 vs. 570.69 ±19.05 AFU, n=6, P<0.01) (Fig. 3B) .
To examine the effect of decreased G6PD activity on the maintenance of cellular glutathione stores, we measured total glutathione levels ( Table 1 ) and found them to be similar in untreated and DHEA-treated BAEC at both baseline (422.9 ± 2.3 vs. 403.8 ± 3.5 µmol/L/mg protein, n=4, P=NS) and following exposure to H 2 O 2 (403.1 ± 14.2 vs. 402.1 ± 14.8 µmol/L/mg protein, n=4, P=NS). Similarly, we found no significant difference in basal levels of GSH between untreated cells and those treated with DHEA (360.5 ± 13.1 vs. 315.9 ± 15.8 µmol/L/mg protein, n=4, P=NS). However, when compared with untreated cells following exposure to H 2 O 2 , DHEAtreated cells demonstrated a more pronounced decrease in GSH levels (227.4 ± 3.5 vs. 67.09 ± 1.0 µmol/L/mg protein, n=4, P<1 × 10 -10 ). DHEA treatment increased basal cellular glutathione peroxidase activity (316.4 ± 46.9 vs. 616.6 ± 93.3 mU/mg protein, n=3, P<0.05), and activity was elevated further following exposure to H 2 O 2 (1474.0 ± 140.1 vs. 2262.0 ± 118.9 mU/mg protein, n=3, P<0.02). In contrast, we found no significant difference in GSSG reductase activity between DHEA-treated cells and control cells (88.4 ± 11.0 vs. 78.3 ± 13.6 mU/mg protein, n=3, P=NS) and, in fact, when exposed to H 2 O 2 , there was actually a significant decrease in GSSG reductase activity compared with untreated cells (145.6 ± 0.8 vs. 85.8 ± 4.1 mU/mg protein, n=3, P<0.008).
Inhibition of G6PD expression and endothelial cell oxidant stress
To establish further the role of G6PD in maintaining endothelial cellular redox state, we diminished G6PD expression by transfection with an antisense phosphorothioate oligodeoxynucleotide to G6PD mRNA (AS). Following AS transfection for 5 h, there was a significant reduction in G6PD protein expression as demonstrated by Western analysis (Fig. 4A) . Compared with vehicle-treated cells, this finding was associated with a decrease in both G6PD activity (76.0 ± 2.0 vs. 18.2 ± 5.1 units/6 min/mg protein, n=6, P<0.0002) (Fig. 4B ) and cellular NADPH levels (0.4 ± 0.01 vs. 0.2 ± 0.001 mmoles/mg protein, n=3, P<9×10 -5 ) (Fig. 4C) (Fig. 4D) .
Glutathione recycling was similarly influenced by reduced G6PD expression (Table 1) . There was no significant difference in basal total glutathione levels between vehicle-treated and AStransfected cells (275. 4 
Endothelial nitric oxide synthase and endothelial oxidant stress
Because G6PD-deficient endothelial cells manifested increased ROS accumulation compared with native endothelial cells when challenged with an oxidant stress, we sought to determine whether eNOS was the source of the increase in cellular ROS production. To examine eNOSmediated ROS production in G6PD-deficient endothelial cells, DHEA-treated and AStransfected BAEC were treated with L-NMMA (100 µM) to inhibit NO, but not superoxide, production by eNOS. DHEA-treated BAEC in the presence of L-NMMA demonstrated increased DCF-fluorescence in the absence of H 2 O 2 exposure (255.5 ± 27.3 vs. 607.6 ± 30.8 AFU, n=8, P<1×10 -9 ) as did AS-transfected BAEC (192.6 ± 15.0 vs. 469.2 ± 13.1 AFU, n=4, P<8×10 -6 ). This response was not observed following treatment with L-NAME in either DHEA-treated (255.5 ± 27.3 vs. 253.82 ± 23.71 AFU, n=8, P=NS) or AS-transfected endothelial cells (192.6 ± 15.0 vs. 160.54 ± 4.0 AFU, n=4, P=NS) (Fig. 5) .
To evaluate the contribution of eNOS to ROS accumulation in the setting of increased oxidant stress, we exposed G6PD-deficient cells to H 2 O 2 , to deplete further NADPH stores and oxidize BH 4 , in the presence of inhibitors of enzymes that generate ROS, including diphenylene iodonium (DPI) (100 µM) to inhibit flavin-containing enzymes, L-NAME (1 mM) to inhibit nitric oxide synthase(s) (NOS), oxypurinol (100 µM) to inhibit xanthine oxidase, and indomethacin (10 µM) to inhibit cyclooxygenase. ROS levels were significantly diminished by the addition of DPI in both DHEA-treated (1009.0 ± 27.3 vs. 339.7 ± 24.8 AFU, n=8, P<2×10 -10 ) and AS-transfected (896.4 ± 17.5 vs. 378.9 ± 43.9 AFU, n=8, P<1×10 -7 ) cells exposed to H 2 O 2 . The addition of L-NAME similarly decreased ROS accumulation in DHEA-treated (1009.0 ± 27.3 vs. 682.6 ± 25.5 AFU, n=8, P<5×10 -7 ) and AS-transfected cells (896.4 ± 17.5 vs. 617.8 ± 12.6 AFU, n=4, P<2×10 -5 ). The addition of L-NAME eliminated the difference in ROS accumulation observed between G6PD-deficient and native endothelial cells following H 2 O 2 exposure (Fig. 6) , which suggests that eNOS-mediated ROS generation may account for this difference.
NO bioavailability in endothelial cells with deficient G6PD activity
To determine if deficient G6PD activity influenced NO production and activity by eNOS, we measured cGMP levels in DHEA-treated and AS-transfected endothelial cells (Table 2) . At baseline, cGMP levels were similar between control and DHEA-treated cells (1.05 ± 0.12 vs. 0.89 ± 0.03 pmol/mg protein, n=3, P=NS); however, DHEA-treated BAEC failed to achieve analogous cGMP levels as control cells in response to the agonists A23187 (5 µM (Fig. 7) . This abrogated response was not due to differences in eNOS protein levels secondary to DHEA treatment or AS transfection as determined by Western analysis, nor was it due to an inherent difference in eNOS activity in the presence of saturating levels of cofactors (data not shown). To demonstrate further that deficient G6PD activity was associated with decreased NO production and not depletion, AS-transfected cells were treated with an NO donor. AS-transfected cells exposed to DEA-NONOate (1 µM) achieved similar cGMP levels compared with control cells (3.92 ± 0.23 vs. 4.25 ± 0.76, pmol/mg protein, n=3, P=NS).
Sepiapterin and oxidant stress in G6PD-deficient endothelial cells
Given that endothelial cells with deficient G6PD activity demonstrated increased eNOSmediated ROS accumulation concomitant with decreased bioavailable NO, we hypothesized that decreased G6PD activity adversely influenced eNOS function by decreasing the stores of necessary cofactors whose synthesis is dependent on NADPH, such as BH 4 . To determine if a relative BH 4 deficiency contributed to eNOS-mediated ROS production, G6PD-deficient BAEC were pretreated with a BH 4 precursor, sepiapterin (100 µM), for 24 h. In DHEA-treated cells, sepiapterin pretreatment decreased basal ROS levels (246. (Fig. 8) .
DISCUSSION
In these studies, we found that vascular endothelial cells with deficient G6PD activity or expression manifest a profound response to oxidant stress and generate abundant ROS, which, in turn, deplete intracellular glutathione stores. As NADPH stores are dependent on efficient G6PD activity, this response, in part, is due to diminished NADPH levels. NADPH, which is required as a reducing equivalent to maintain cellular redox state, additionally serves as a cofactor for several homeostatic enzymes (Fig. 9) . In G6PD-deficient endothelial cells, eNOS appears to be a significant source of cellular ROS production. Concomitant with an increase in eNOS-mediated ROS generation, bioactive NO levels, as determined by cGMP levels in agonist-stimulated cells, are diminished. This reduction in detectable bioavailable NO could not be attributed to differences in eNOS protein levels or enzyme activity (when determined in the presence of adequate concentrations of added cofactors). Yet, as G6PD deficiency results in decreased NADPH stores, which may, in turn, modulate BH 4 levels, and, because both NADPH and BH 4 are required cofactors for optimal eNOS activity, we treated BAEC with a BH 4 precursor, sepiapterin, to determine whether G6PD deficiency-mediated cofactor depletion accounted for the increase in ROS production by eNOS. It has been demonstrated previously in cell-free systems that deficient BH 4 levels promote eNOS-mediated superoxide generation (12, 13) . In support of this hypothesis, we demonstrated that sepiapterin partially abrogated eNOS-mediated ROS production.
G6PD, the first and rate-limiting enzyme in the pentose phosphate pathway, is an important source of cellular NADPH. In this manner, G6PD contributes to the maintenance of cellular redox homeostasis by supplying reducing equivalents for efficient glutathione reductase activity and glutathione recycling. There is a mounting body of evidence to suggest that G6PD importantly modulates the vascular endothelial cell response to oxidant stress and that deficient G6PD activity is associated with adverse sequelae. For example, bovine aortic endothelial cells with decreased G6PD activity are more prone to undergo apoptosis in the presence of high concentrations of H 2 O 2 (500 uM) than endothelial cells with normal G6PD activity (8) . This finding is not surprising, as G6PD and GSSG reductase activities have been shown to influence the kinetics of NADPH-dependent H 2 O 2 elimination (20) . Hyperglycemia, which is associated with increased oxidant stress in aortic endothelial cells, has recently been shown to exert its deleterious effects, in part, by inhibiting G6PD activity (21) . In our studies, normal vascular endothelial cells respond to a modest H 2 O 2 challenge by increasing G6PD activity to respond to a decrease in cellular GSH levels and enhance glutathione recycling. We have additionally demonstrated here that G6PD-deficient BAEC experience a more pronounced oxidant stress as shown by the marked increase in cellular ROS accumulation and the corresponding decrease in GSH levels.
The association of G6PD activity with NOS activity and NO generation remains controversial; however, to date, this relationship has been explored only in the setting of markedly elevated concentrations of endogenous NO, generated via the induction of iNOS expression, or exogenous NO from NO donors. Some evidence suggests that deficient G6PD activity promotes nitrosative stress and NO-mediated cellular injury. For example, in rat astrocytes, induction of iNOS by lipopolysaccharide is accompanied by an increase in G6PD mRNA expression and enzyme activity. Inhibition of G6PD activity with DHEA results in a decrease in cellular GSH levels, which was abolished by the addition of AMT, an inhibitor of iNOS, thereby suggesting that G6PD is protective against iNOS-mediated GSH depletion (22) . Similarly, in human foreskin fibroblasts isolated from G6PD-deficient patients, exposure to sodium nitroprusside promoted apoptosis, in contrast to its growth-stimulatory effect in wild-type fibroblasts. Overexpression of G6PD in deficient cells restored the growth-enhancing effects of this NO donor (4). Other investigators have shown that inhibition of G6PD activity with DHEA is associated with a decrease in NOS expression and activity. In an ex vivo peritoneal macrophage preparation from male p53 wild-type and p53 -/-mice, treatment with DHEA significantly reduced NOS expression and NO generation (23) . Similarly, nitrite formation in response to interleukin-1β in isolated rat islets or RINm5F insulinoma cells was inhibited by DHEA-mediated G6PD inhibition (24, 25) . These seemingly conflicting results may be partially explained by the use of inflammatory mediators to induce iNOS expression and differences in the cell types studied.
To overcome these limitations, we evaluated the association between G6PD and eNOS in endothelial cells and thereby avoided the addition of exogenous mediators to induce iNOS expression with its concomitant nitrosative stress. To characterize the role of G6PD in modulating eNOS activity, we initially made the cells G6PD-deficient and challenged them with an oxidant stress. Only after the addition of inhibitors of enzymes that generate ROS, specifically DPI and L-NAME, was it apparent that eNOS, a flavin-containing enzyme, was contributing to cellular oxidant stress. This observation was confirmed by the differential response to the NOS inhibitors L-NAME, which inhibits both NO and superoxide production by NOSs, and L-NMMA, which inhibits only NO production. There was a significant decrease in ROS production only in the presence of L-NAME. This finding is not entirely surprising as deficient G6PD activity is associated with a reduction in NADPH stores. This, in turn, may influence levels of BH 4 , another essential cofactor for NOS activity whose salvage via dihydrofolate reductase is dependent on NADPH (10). It has been recognized that in the setting of decreased cofactor availability, NOS may preferentially generate superoxide anion. At low concentrations of L-arginine, the neuronal isoform of NOS has been shown to synthesize both superoxide and H 2 O 2 (11) . In cell-free systems, eNOS generates superoxide in the setting of deficient L-arginine and BH 4 stores (12, 13) . In U937 cells, characterized by impaired synthesis of BH 4 , transfected eNOS generates superoxide that has been localized to a subunit of the enzyme with inherent NADPH oxidase activity (9).
In our system, decreased G6PD activity did not influence levels of eNOS protein expression as demonstrated by Western analysis; however, it was associated with a reduction in bioavailable NO as revealed by cGMP levels following agonist stimulation. There are several possible explanations for this observation. First of all, treatment with DHEA or an antisense oligodeoxynucleotide may adversely affect enzyme function. To evaluate this possibility we determined eNOS activity by the conversion of L-arginine to L-citrulline and found that there was no inherent difference in enzyme activity (with exogenous cofactor addition in the assay). Secondly, because there is increased ROS formation and decreased NO synthesis from NOS, bioavailable NO may be rapidly consumed in a 1:1 stoichiometric reaction to form peroxynitrite. DCF fluorescence may also detect peroxynitrite; however, in our system, DCF fluorescence was increased in G6PD-deficient cells treated with L-NMMA, suggesting that we were measuring ROS alone and not peroxynitrite in this experiment. Finally, as previously suggested, G6PD deficiency is associated with decreased eNOS cofactor availability and, therefore, eNOS may preferentially synthesize superoxide instead of NO.
To determine whether replenishing deficient cofactors may reverse eNOS-mediated superoxide formation we pretreated G6PD-deficient BAEC with sepiapterin, a precursor of BH 4 . In cells pretreated with sepiapterin there was a significant reduction in detectable ROS levels following exposure to H 2 O 2 . In cultured endothelial cells exposed to the NO donor SIN-1 3-morpholinosydnonmine-hydrochloride, which releases both NO and superoxide, pretreatment with sepiapterin was shown to increase intracellular BH 4 levels and reduce cell death (26) . In contrast to these observations, superoxide production by pterin-free nNOS in the presence of low concentrations of L-arginine was diminished by pretreatment with BH 4 only and not by sepiapterin. When L-arginine levels were repleted, the addition of sepiapterin only resulted in an approximate 30% decrease in nNOS-mediated superoxide production by facilitating the binding of L-arginine (27) . Finally, in our system, despite reduced NADPH levels, conversion of sepiapterin to BH 4 by dihydrofolate reductase may not be influenced adversely and intracellular BH 4 content may be repleted effectively to scavenge H 2 O 2 and decrease cellular ROS accumulation (28) . Alternatively, sepiapterin itself, as well as BH 4 , may scavenge ROS directly and thereby confer protection on cells against oxidant stress.
G6PD is increasingly recognized as an important antioxidant enzyme in vascular cells to restore intracellular redox state in the setting of increased oxidant stress. We now show, in vascular endothelial cells, that deficient G6PD activity promotes ROS accumulation by failing to maintain intracellular reducing equivalents in the form of NADPH. In addition, eNOS, which under basal conditions generates NO to maintain reduced vascular tone, appears to contribute significantly to intracellular ROS formation at the expense of bioavailable NO. By depleting bioavailable NO and increasing cellular ROS, deficient G6PD activity promotes an oxidizing environment and thereby adversely modulates the intracellular milieu and endothelial function. 2 . DHEA, G6PD activity, and NADPH levels. A) BAEC were treated with DHEA (100 µmol/L) for 24 h and G6PD activity was determined (n=6). G6PD activity is expressed as units/6 min/mg protein, and data are expressed as mean ± SE. * P < 0.0001 vs. -DHEA. B) Corresponding NADPH levels were measured in DHEA-treated BAEC (n=3). NADPH is measured as mmol/L/mg protein and reported as mean ± SE. * P < 0.03 vs. -DHEA. . Antisense phosphorothioate oligodeoxynucleotide to G6PD and G6PD expression, activity, NADPH levels, and ROS production in BAECs. A) BAEC were transfected with an antisense oligodeoxynucleotide to G6PD mRNA (+AS) for 5 h or with the Oligofectin I vehicle (-AS) and (A) G6PD protein expression was determined by Western analysis. B) G6PD activity (units/6 min/mg protein) was determined in transfected cells (n=6), and data are presented as mean ± SE. *P < 0.0002 vs. -AS. C) Cellular NADPH levels were measured (n=3) as mmol/L/mg protein and reported as mean ± SE. *P < 9 × 10 -5 vs. -AS. D) Transfected BAEC were exposed to H 2 O 2 (100 µmol/L) for 4 h, and cellular ROS production was determined by DCF fluorescence (n=6). Fluorescence is expressed in arbitrary units, and data are reported as mean ± SE. *P < 1 × 10 -8 vs. -H 2 O 2 . for 1 h with L-NAME (1 mmol/L) to inhibit nitric oxide (NO) and superoxide production by eNOS, or L-NMMA (100 µmol/L) to inhibit superoxide production alone. Cellular ROS production was measured by DCF fluorescence (n=4) and expressed in arbitrary units. The data are reported as mean ± SE. *P < 8 × 10 -6 vs. +AS, no addition. (100 µmol/L) for 24 h and then exposed to H 2 O 2 (100 µmol/L) for 4 h and cellular ROS production was determined by DCF fluorescence (n=6) and expressed in arbitrary units. + P < 3.7 × 10 -6 vs. -Sepiapterin, *P < 1.6 × 10 -8 vs. -Sepiapterin, #P < 1.3 × 10 -7 vs. -Sepiapterin.
Fig. 9
Figure 9. Central role of NADPH. NADPH serves as a cofactor for the reduction of oxidized glutatione (GSSG) to its reduced form (GSH) by glutathione reductase (GR), the synthesis of tetrahydrobiopterin (BH 4 ) from its precursor (BH 2 ) by dihydrofolate reductase (DHFR), the conversion of glucose-6-phosphate (G6P) to 6-phosphogluconate (6GP) by glucose-6-phosphate dehydrogenase (G6PD), and the synthesis of nitric oxide (NO) from L-arginine by endothelial nitric oxide synthase (eNOS).
